Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 353 of 5804
-
New drug aimed at slowing pancreatic cancer shows promise in early trial
Disease control Not yet recruitingThe study is being conducted to to explore the reasonable dosage and evaluate the efficacy, safety and tolerability of HLX43 (Anti-PD-L1 ADC) in Patients with Pancreatic ductal adenocarcinoma (PDAC)
Phase: PHASE2 • Sponsor: Shanghai Henlius Biotech • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
New drug zorifertinib aims to fight lung cancer in the brain
Disease control Recruiting nowThis study is a patient-centered, two-group, three-cohort, multi-center, prospective study to further evaluate the survival benefits and safety of zorifertinib as a first-line treatment in EGFRm+ advanced NSCLC patients with CNS metastases, and to compare the clinical value of zo…
Sponsor: Alpha Biopharma (Jiangsu) Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
New drug combo shows promise for Hard-to-Treat breast cancer
Disease control Recruiting nowPhase I: Characterize safety and tolerability of GVV858 as a single agent and in combination with fulvestrant or letrozole. Identify dose range for optimization/recommended dose for further clinical evaluation. Phase II: Further characterize the safety and tolerability of GVV858…
Phase: PHASE1, PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jul 09, 2026 00:00 UTC
-
New hope for Hard-to-Treat breast cancer: Two-Drug cocktail shows promise
Disease control Recruiting nowThis is a randomized, open-label, phase Ib study to assess safety and efficacy of sacituzumab govitecan plus nivolumab or sacituzumab govitecan plus a fixed dose combination of nivolumab and relatlimab in patients with any programmed cell death-ligand 1 (PD-L1) status metastatic,…
Phase: PHASE1, PHASE2 • Sponsor: Yale University • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
New hope for painful skin condition: experimental drug aims to reduce abscesses
Disease control Recruiting nowThis is a multinational, randomized, double-blind, placebo-controlled, Phase 2, dose finding study to evaluate the efficacy and safety of different doses of SAR445399 in adult participants with moderate to severe hidradenitis suppurativa. The purpose of this study is to assess t…
Phase: PHASE2 • Sponsor: Sanofi • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
New 3D-Printed knee patch could help regrow damaged cartilage
Disease control Recruiting nowThe goal of this clinical trial is to learn if a new treatment works to help regrow knee cartilage in people with knee cartilage damage. The main questions it aims to answer are: Does the treatment help the knee work better and lower pain more than the standard surgery? Is the …
Phase: PHASE4 • Sponsor: ROKIT Healthcare • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
Could stem cells restore erectile function in diabetic men?
Disease control Recruiting nowThe goal of this prospective randomized controlled clinical study is to evaluate the effectiveness and safety of intracavernosal injections of umbilical cord-derived mesenchymal stem cells (MSCs) and umbilical cord-derived MSC-derived exosomes in men aged 25 to 75 years with diab…
Phase: PHASE2, PHASE3 • Sponsor: Ankara City Hospital Bilkent • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
New combo aims to stop liver cancer from coming back
Disease control Not yet recruitingThis study is a prospective, randomized controlled, phase II trial evaluating the efficacy and safety of neoadjuvant therapy with Sintilimab combined with SBRT in patients with resectable hepatocellular carcinoma. After meeting the inclusion and exclusion criteria and providing …
Phase: PHASE2 • Sponsor: Lei ZHAO • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
Engineered immune cells take aim at a common cancer target in Hard-to-Treat tumors
Disease control Recruiting nowAn open label, single/multiple dose exploratory clinical study to evaluate the safety, efficacy, and pharmacokinetics of autologous humanized anti-claudin18.2 chimeric antigen receptor T cell in advanced solid tumor.
Phase: EARLY_PHASE1 • Sponsor: Celest Therapeutics (Shanghai) Co., Ltd. • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
New combo therapy aims to boost immune attack on Hard-to-Treat lymphoma
Disease control Recruiting nowThis phase I/II trial tests the safety, side effects, and best dose/regimen of ST-067 in combination with CD19-directed chimeric antigen receptor (CAR) T-cell therapy (liso-cel) and how well it works in treating patients with large B-cell lymphoma (LBCL) that has come back after …
Phase: PHASE1, PHASE2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
CAR-T therapy takes on tough blood disorder in early trial
Disease control Not yet recruitingThis is a multicenter, open-label, single-arm Phase I clinical trial to evaluate the safety and tolerability of Inaticabtagene Autoleucel Injection treatment in autoimmune hemolytic anemia that has failed at least three lines of treatment.
Phase: PHASE1 • Sponsor: Juventas Cell Therapy Ltd. • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
New pill could ease stiffness and pain for ankylosing spondylitis patients
Disease control Recruiting nowThis clinical trial is a multicenter, randomized, double-blind, controlled phase III clinical study.
Phase: PHASE3 • Sponsor: Jiangsu vcare pharmaceutical technology co., LTD • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
New psoriasis cream shows promise in major trial
Disease control OngoingThis is a multi-center, randomized, investigator-blinded, calcipotriol and betamethasone dipropionate gel and vehicle-controlled phase 3 clinical study to evaluate the efficacy and safety of MC2-01 cream in the treatment of Chinese plaque psoriasis to assess the efficacy and safe…
Phase: PHASE3 • Sponsor: Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Could umbilical cord stem cells help failing hearts?
Disease control Recruiting nowB2278 is a human umbilical cord mesenchymal stem cell (HucMSCs) injection derived from the umbilical cord. It has the advantages of stronger immune regulation, stronger expansion capacity, lower immunogenicity, and greater accessibility. The preliminary research results indicated…
Phase: PHASE1, PHASE2 • Sponsor: Tasly Pharmaceutical Group Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
New cell therapy combo targets tough stomach cancers
Disease control Recruiting nowThe goal of this clinical trial is to learn the safety of tumor neoantigen vaccine combined with neoantigen vaccine induced T-cell in treating advanced gastric cancer in adults. It will also learn if the combined treatment works to treat advanced gastric cancer. The main questio…
Phase: PHASE1 • Sponsor: Jia Wei • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
New combo aims to supercharge immune attack on lymphoma
Disease control Recruiting nowTargeted therapy against the CD30 molecule has achieved some progress in CD30-positive Hodgkin lymphoma, but its efficacy remains unsatisfactory. Previous studies have demonstrated that N-glycan modifications in the extracellular domain of target proteins can disrupt immune synap…
Phase: PHASE1, PHASE2 • Sponsor: Chinese PLA General Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
Ancient herbs meet modern medicine in new fertility trial for women with low egg reserve
Disease control Not yet recruitingThis study aims to evaluate the superiority of an integrated traditional Chinese and Western medicine regimen ("Xiehe DOR Bushen Tongzhi Formula" + ovulation induction therapy with ovulation monitoring and timed intercourse) compared to standard treatment alone (placebo + ovulati…
Phase: PHASE3 • Sponsor: Peking Union Medical College Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
New obesity drug HRS9531 takes on semaglutide in major trial
Disease control OngoingThis study is a multicenter, randomized, open-label, parallel-controlled, phase III study to compare the efficacy, safety, and tolerability of HRS9531 versus semaglutide once weekly (QW) in adult subjects with obesity
Phase: PHASE3 • Sponsor: Fujian Shengdi Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
New hope for sarcoma patients: novel drug combo enters human trials
Disease control Recruiting nowWhat is this study about? This is a medical research study testing a new drug combination ("Paclitaxel Polymer Micelles" + "Gemcitabine" + "Targeted Therapy") for patients with locally advanced unresectable or metastatic bone and soft tissue sarcomas whose disease has progressed …
Phase: PHASE2 • Sponsor: Shanghai 6th People's Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
New drug cocktail aims to control follicular lymphoma without chemo
Disease control Recruiting nowThis study is planned to prospectively evaluates the efficacy and safety of the zanubrutinib, obinutuzumab, and lenalidomide (ZGR) combination regimen in treatment-naïve follicular lymphoma (FL) patients in a Chinese population.
Phase: PHASE2 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC